MacuCLEAR Inc. is a specialty clinical-stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye. MacuCLEAR has an active IND for MC-1101 and has completed a novel and successful Phase Ib/POC human clinical trial. MC-1101, MacuCLEAR’s lead compound, is a patented, topically delivered drug for treating and stopping the progression of dry Age-related Macular Degeneration (AMD). Subsequent targets beyond dry AMD include diabetic macular edema. In April 2007, MacuCLEAR completed a private placement of funds to complete preclinical studies and to advance promising pipeline products through FDA Investigational New Drug (IND) application and subsequent IND activation and into human clinical development. In January 2009, MacuCLEAR received approval for $1.7M from the Texas Emerging Technology Fund (TETF) to further the development of MC-1101. The Company met the TETF Qualifying Funding Transaction by raising more than $500K of new money in October of 2010. MacuCLEAR qualified for the IRS/HHS Qualifying Therapeutic Development Project and has received a grant of $245K against its clinical development costs in 2009. This is non-dilutive and tax-free funding and further indication of the importance of MacuCLEAR’s approach to addressing dry AMD.